Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Ultimo, NSW 2007, Australia.
School of Pharmaceutical Sciences, Jaipur National University, Jagatpura, 302017 Jaipur, India.
Biomed Pharmacother. 2018 Aug;104:87-93. doi: 10.1016/j.biopha.2018.05.045. Epub 2018 May 14.
The Special AT-rich Sequence Binding Protein 1 (SATB1) is a chromatin organiser and transcription factor which regulates numerous cellular processes such as differentiation, proliferation and apoptosis through effects on gene expression. SATB1 undergoes various post-translational modifications, which determine its interaction with co-activators and co-repressors to induce regulation of gene transcription. SATB1 is an identified oncogene, its increased expression is associated with poor prognosis in many cancers. This paper provides a review on SATB1-mediated immune responses and on its target genes in the context of tumorigenesis and tumour progression. Specifically, we discuss the role of SATB1 in tumour immunity, Epithelial to Mesenchymal Transition (EMT), metastasis and multidrug resistance. Therapeutic targeting of aberrant SATB1 may be an important strategy in the treatment of cancer.
特异性富含 AT 的序列结合蛋白 1（SATB1）是一种染色质组织蛋白和转录因子，通过影响基因表达，调节细胞分化、增殖和凋亡等多种细胞过程。SATB1 经历多种翻译后修饰，决定其与共激活因子和共抑制因子的相互作用，从而诱导基因转录的调节。SATB1 是一种已确定的癌基因，其表达增加与许多癌症的预后不良有关。本文综述了 SATB1 介导的免疫反应及其在肿瘤发生和肿瘤进展中的靶基因。具体来说，我们讨论了 SATB1 在肿瘤免疫、上皮间质转化（EMT）、转移和多药耐药中的作用。靶向异常 SATB1 可能是癌症治疗的重要策略。
